AFFISE
24.2.2021 14:02:11 CET | Business Wire | Press release
Affise , the global technology leader in partnerships management and automation, today announced a Series A funding round worth $8 million. This recent funding round, led by Leta Capital and TMT Investments, follows a period of impressive growth for the company. Founded in Vilnius, Lithuania in 2016, Affise has doubled its revenue every year and now employs over 120 professionals in six offices around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005005/en/
“Affise has shown remarkable international growth, which we are happy to intensify even further with the investment round,” said Alexander Chachava, Managing partner at Leta Capital. “We can see that performance marketing becomes essential across many new channels which were difficult to measure until recently. The company empowers its clients with the real tools to boost the business, and we believe that Affise is going to become an industry-standard in performance marketing automation software.”
“The funding round will help the team focus on geographic expansion in regions where advertising, affiliate marketing and economy as a whole are growing, namely the States and Asian countries. With such a great team and product, we believe in success,” - commented Artyom Inyutin, Co-founder & Head of Investments, TMT Investments.
As the partnership marketing industry continues an impressive growth of 10%, every year, its 2021 value is estimated to reach $1.2B. Affise endeavours to utilize the funding to expand its product suite, providing marketers with a single platform to automate and scale partnerships. Following a tremendous success entering the Chinese market in 2019, Affise plans to increase its presence in North America, LatAm, and SEA, as well as cement its leadership in Europe, Israel and India.
“Partnerships management is becoming the vital component of the marketing technology stack, and Affise has established itself as a leader in this fast-growing category,” said Stanislau Litvinau, CEO and Co-Founder, Affise. “Our commitment to representing the marketers’ interests has gained the trust of the leading agencies and networks, and we see significant potential to capture additional opportunity in the market. One strategy we’re aiming to complete with this funding is entering the adjacent market of direct advertisers and brands, empowering them to grow their marketing channel with affiliate programs”.
Affise works with over 1,000 customers, including leading brands and agencies such as Wargaming, Xapads, Hypercentage, Kismia, Mobavenue, Zorka.Mobi, Mobligent. The company boasts connections to a conglomerate of over 300,000 partners, which accelerates business growth. The winner of 14 awards in the last year alone, Affise has been crowned the leader in three categories by G2: Partner Management, Marketing Analytics, and Digital Analytics.
“The market evolution from traditional affiliates to new performance channels (influencers, brand-to-brand and other), along with the skyrocketing growth in e-Commerce in 2020, will encourage more small and medium advertisers to launch their affiliate programs'' - Dmitrii Zotov, CTO and Co-Founder, Affise. “This trend will generate demand for technological solutions to start and manage affiliate programs from scratch and achieve incremental growth. Thus, this funding round will enable us to follow Affise’s mission of empowering marketers with the tools needed to catapult their success and make accurate strategic decisions. This will drive innovations and transparency across the industry”.
About Affise
Affise is a partnership marketing platform for brands, advertisers and agencies to automate and scale their partner relations via all possible performance marketing channels: traditional affiliates, influencers, networks and agencies. The synergy of technology and the long standing experience allows Affise’s clients to make partnerships manageable and revenue predictable marketing channel. To learn more, visit www.affise.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005005/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
